BioPharmSignal logoBioPharmSignal

Biotech News

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

NuCana plc (NCNA)NuCana plcCompany update

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented data at the European Society for

Related news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

KURAKura Oncology2026-06-11 12:02 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

BMEABiomea Fusion2026-08-13 11:00 EST

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

LYELLyell Immunopharma2026-06-12 16:45 EST

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

CGEMCullinan Therapeutics, Inc.2026-06-06 09:15 EST

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

BNTXBioNTech2026-08-20 09:30 EST

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

View all latest news

NuCana plc

ProTide Oncology Company NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells. NUC-7738 NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor...

Recent company news

NCNANuCana plc2026-08-13 20:01 EST

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-06-01 12:00 EST

NuCana Appoints Ian Webster as Chief Financial Officer

NCNANuCana plc2026-05-14 20:01 EST

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

NCNANuCana plc2026-03-19 20:01 EST

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NCNANuCana plc2026-01-06 13:00 EST

NuCana Appoints Theresa Bruce as Chief Operating Officer

Stock data

Close
1.52 USD
Market cap
8.62M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States